High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis Reply
Open Access
- 14 June 2020
- journal article
- letter
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 201 (12), 1579-1580
- https://doi.org/10.1164/rccm.202002-0359LE
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human TuberculosisClinical Pharmacokinetics, 2019
- Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in HaitiClinical Infectious Diseases, 2019
- Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysisPLoS Medicine, 2018
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010